Haystack oncology and rutgers cancer institute collaborate to use haystack mrd™ in clinical study of early-stage triple-negative breast cancer

Baltimore , dec. 14, 2023 /prnewswire/ -- haystack oncology, a quest diagnostics (nyse: dgx) company, has entered into a collaboration with rutgers cancer institute of new jersey to use haystack oncology's industry-leading personalized mrd technology (haystack mrd™) to help evaluate therapeutic response and provide molecular insights for a rutgers cancer institute clinical trial examining early-stage triple-negative breast cancer (tnbc) patients undergoing treatment in the adjuvant setting with liposomal doxorubicin and carboplatin. rutgers cancer institute together with rwjbarnabas health is the state's only national cancer institute-designated comprehensive cancer center.
DGX Ratings Summary
DGX Quant Ranking